Introduction
Fat is an important component of parenteral nutrition (PN) that serves several purposes. Parenteral fat provides essential fatty acids (EFAs) that cannot be synthesized de novo, including the long-chain polyunsaturated omega-3 and omega-6 fatty acids. Omega-3 fatty acids include α-linolenic acid, which can be converted through a series of elongation and desaturation steps to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omega-6 fatty acids include the parent compound linoleic acid, which can be enzymatically converted to arachidonic acid by the same elongases and desaturases that act on omega-3 fatty acids. Fat is also a dense source of calories that prevents the need for excess carbohydrates to meet caloric demands. It has been demonstrated that fat-free, highcarbohydrate PN can result in upregulation of de novo lipogenesis and hepatic fat accumulation. [1] [2] [3] Intravenous fat is compounded as an oil-in-water emulsion. Dispersions used to create stable fat emulsions are composed of an emulsifier (ie, egg phospholipid), glycerin, a stabilizer such as sodium oleate, and water. The oil contains fatty acids that confer nutrition value, fulfill the EFA requirement, and are precursors of lipid-derived second messengers and bioactive mediators. For example, arachidonic acid is a precursor of thromboxane and prostacyclin, which are important in platelet aggregation and coagulation. Arachidonic acid is also metabolized to produce proinflammatory leukotrienes and prostaglandins. EPA and DHA are precursors of series 5 leukotrienes and series 3 prostaglandins, 4 resolvins, defensins, and maresins, which are anti-inflammatory mediators. 5 The oil in lipid emulsions also contains excipients, including phytosterols and α-tocopherol. Phytosterols are structurally similar to cholesterol and abundant in plant-based oils. They are poorly metabolized by mammals when administered intravenously and can inhibit the hepatic farsenoid X receptor to 6 α-Tocopherol (vitamin E) is an antioxidant with anti-inflammatory properties 7 that is added to fish oil (FO) to prevent it from becoming rancid. Plant-based oils contain very little α-tocopherol.
The oils in emulsions can have different physiologic effects by virtue of their differing fatty acid composition and additive content. [8] [9] [10] Soybean oil (SO) is rich in omega-6 fatty acids, with linoleic acid constituting ~50% of its fatty acid content. It is rich in phytosterols and contains little α-tocopherol. FO contains an abundance of omega-3 fatty acids, fewer omega-6 fatty acids, high levels of α-tocopherol, and only trace amounts of phytosterols. PN-associated liver disease-characterized by hepatic inflammation and cholestasis that can progress to cirrhosis and end-stage liver disease if untreated-is associated with use of SO parenteral fat sources.
11 FO as the parenteral fat source can reverse cholestasis. 12, 13 While some studies have concluded that a high phytosterol level renders SO hepatotoxic, 14 others have suggested that the abundance of α-tocopherol and omega-3 fatty acid precursors of anti-inflammatory mediators renders FO hepatoprotective. 15 Olive oil is rich in nonessential omega-9 monounsaturated fatty acids, and coconut oil is rich in medium-chain triglycerides. Both oils contain very few EFAs. While the effect of olive oil as a sole parenteral fat source has not been reported, use of coconut oil as the sole fat source can result in EFA deficiency. 16 Parenteral lipid emulsions and their oil components are required to meet specific pharmacopeial criteria meant to ensure the integrity and safety of emulsions for parenteral use. In the United States, chapter 729 of the United States Pharmacopeia (USP) requires that parenteral fat emulsions have a mean fat globule size <500 nm and a percentage of fat globules >5 μm (PFAT5) ≤0.05%. 17 These criteria are in place to avoid coalescence of emulsions and maintain stability during transport and storage prior to use. [18] [19] [20] Oil sources for parenteral lipid emulsions also have pharmacopeial monographs that define criteria for safe use in pharmaceutical applications. FO has 2 distinct monographs in the European Pharmacopoeia. Monograph 1912-"fish oil, rich in omega-3 acids," or natural FO (NFO)-contains a minimum of 28% omega-3 fatty acids (at least 22% EPA and DHA) and reflects the fatty acid content of the oil extracted from fish. 21 Monograph 1352-"omega-3 acids," or purified FO (PFO)-originates from NFO but is further enriched in EPA, DHA, and total omega-3 fatty acids (at least 45% EPA and DHA and a least 60% omega-3 fatty acids). 22 Given the anti-inflammatory properties of the omega-3 fatty acids, use of PFO in parenteral emulsions to provide more anti-inflammatory mediators per unit volume is an attractive possibility. However, comparisons of the effects of NFO and PFO have not been reported in models of PN dependence or in human populations. The purpose of this study is to compare the effects of PFO and NFO as oil sources in parenteral lipid emulsions in a murine model.
Materials and Methods

Lipid Emulsion Production
Lipid emulsions were generated via high-pressure homogenization. Figure 1 demonstrates a schematic of the emulsion formulation process. To formulate the lipid dispersion, Lipoid E80 egg phospholipid (Lipoid LLC, Newark, NJ) was added to heated (75°C-90°C) USP-grade sterile water for injection (Hospira, Lake Forest, IL) under high-speed shear mixing conditions. Temperature was allowed to decrease to 40°C-45°C. Sodium oleate (Lipoid LLC) was then added, and shear mixing continued at 3900-4000 RPM for 40 minutes. Heated sterile water for injection was serially added to maintain the temperature at 40°C-45°C. Glycerin (Sigma-Aldrich, St Louis, MO) was added under continuous shear mixing. This resulted in a dispersion composed of 12% egg phospholipid, 25% glycerin, and 0.3% sodium oleate. The crude dispersion was transferred to a Panda Plus homogenizer (GEA Niro Saovi, Columbia, MD), homogenized at 9000 psi at 40°C-45°C for 20 cycles, and filtered through a 0.45-μm membrane, with the pH adjusted to 10.4 with 0.5N sodium hydroxide. All steps were performed under a nitrogen atmosphere.
Emulsions were made with the following oils: USP-grade SO (Spectrum Chemicals, New Brunswick, NJ), NFO, PFO with 66% of the fatty acids as triglycerides (PFO66), and PFO with 90% of the fatty acids as triglycerides (PFO90; NFO and both PFO varieties are from Pronova Biopharma, Oslo, Norway). NFO contained 41% of fatty acids as EPA and DHA, and ≥94% of total fatty acids were in triglyceride form. PFO66 contained 91.6% omega-3 fatty acids (77.5% EPA and DHA) purified and reesterified such that 66% of the fatty acids were in triglyceride form (PFO66) and the remaining 34% were present as diglycerides, monoglycerides, ethylesters, and free fatty acids. PFO90 contained 66.2% of fatty acids as EPA and DHA and 90.5% of all fatty acids in triglyceride form. Table 1 demonstrates the properties of NFO according to its certificate of analysis. NFO met the majority of the European Pharmacopoeia monograph 1912 specifications. Table 2 demonstrates the properties of the PFO66 and PFO90 oils, which met the majority of the European Pharmacopoeia 1352 specifications. Analyses were completed in adherence to USP 401 specifications. Table 2 outlines the emulsions and their abbreviations. The final composition of each emulsion was 20% oil, 1.2% egg phospholipid, 2.5% glycerin, and 0.03% sodium oleate. This composition is similar to currently available commercial products. Curved arrows indicate addition of the substance noted above the arrow. RPM, revolutions per minute (in the high-speed shear mixer); SWFI, sterile water for injection. "Cycles" refer to the number of times the total volume of dispersion/emulsion passes through the homogenizer at the pressure indicated. All steps are performed under a nitrogen gas atmosphere. To compound the emulsions, oil was added to the dispersion agent in a thin stream under continuous shear mixing conditions at 3500-4500 RPM for 40-45 minutes, at a temperature of 40°C-45°C. The resulting crude emulsions were transferred to the Panda Plus homogenizer and homogenized at 5000 psi at 40°C-45°C for no fewer than 9 cycles of the emulsion. The pH of the emulsions was buffered to >8.8 with 0.1N sodium hydroxide. All steps of the compounding process were performed under a nitrogen atmosphere. The finished emulsions were aliquoted into 20-mL glass serum vials, and headspaces were flooded with nitrogen gas before sealing. All vials were heat sterilized. To determine whether emulsions met USP 729 specifications, each product underwent independent mean globule size and PFAT5 testing (Micro Measurements, Deerfield, IL). Table 3 specifies the 4 emulsions formulated in the laboratory that were used in this study.
Murine Tolerance Experiments
All experiments were approved by the Boston Children's Hospital Institutional Animal Care and Use Committee. As the purpose of this study was to assess solely the safety and tolerance of the emulsions and not to provide a source of calories or EFAs, animals were fed a standard chow diet throughout the experiments. Six-week-old to 8-week-old C57BL/6 male mice (Jackson Labs, Bar Harbor, ME) maintained on an ad lib chow diet were injected with 2.4g/kg/d of one of the laboratory compounded emulsions (20% SO, 20% NFO, 20% PFO66, or 20% PFO90), the commercially available 10% FO emulsion Omegaven (OM; Fresenius Kabi, Bad Homburg, Germany), or saline every other day for 19 days. The commercial FO emulsion and saline control were included, as the commercial FO emulsion is well tolerated and has been safe to use in this mouse model. Thus, the use of the commercial FO emulsion afforded the ability to assess whether the process used to compound the test emulsions yielded similar histologic findings and to ascertain whether the compounding technique may be responsible for observed findings in the groups receiving the test emulsions. Body mass was measured prior to each tail vein injection, and observed responses to each injection were recorded. After 19 days, animals were euthanized. Livers, spleens, and kidneys were weighed and masses recorded. Livers, spleens, and lungs were fixed in 10% formalin for hematoxylin and eosin histologic analysis. A board-certified pathologist blinded to the experimental groups performed the histologic analysis.
Results
USP 729 Standards
The PFO66 emulsion met both mean globule size and PFAT5 pharmacopeial standards (210 nm and 0.03%, respectively). The SO emulsion met pharmacopeial standards, with a mean globule size of 279.8 nm and PFAT5 of 0.019%. The NFO emulsion met the mean globule size pharmacopeia standard at 249 nm but exceeded the 0.05% PFAT5 threshold at 0.06%. The PFO90 emulsion also met mean globule size specifications at 215 nm but exceeded the PFAT5 threshold at 0.059%.
Clinical Tolerance
Animals in all treatment groups demonstrated similar weight gain over the study period (data not shown). Mice receiving the NFO, SO, OM, and saline intravenously exhibited no symptoms following each injection. Animals receiving the PFO66 emulsion became transiently tachypneic and lethargic for ~1 minute following each injection before returning to normal respiratory and activity status.
Given that the SO, NFO, and PFO66 emulsions were made with the same dispersion using the same compounding methods and that the SO and NFO were well tolerated, we hypothesized that a property of the oil, rather than the dispersion or the compounding process, resulted in the poor tolerance of the PFO66 emulsion. We next hypothesized that improving the reesterification efficiency of PFO may result in improved tolerance of a 20% PFO parenteral emulsion. When the tolerance 
Gross Organ Assessment and Histology
At organ procurement, animals administered the PFO66 had marked hepatosplenomegaly as compared with the SO, NFO, OM, and saline groups. Despite being asymptomatic with intravenous administration of the PFO90 emulsion, animals in this group had splenomegaly at time of organ procurement ( Figure 2) . On histologic analysis, the PFO66 and PFO90 groups had hepatic and splenic lipid-laden macrophages with no necrosis or evidence of inflammation, as well as scattered pulmonary fat deposits. The SO, NFO, OM, and saline groups had histologically normal livers, spleens, and lungs ( Figure 3 ).
Discussion
PFO emulsions are modified to contain a higher proportion of the anti-inflammatory fatty acids EPA and DHA than NFO. Thus, PFO represents an attractive potential parenteral fat source for improving inflammatory states in chronically PN-dependent patients. 23 Use of PFO as a parenteral fat source also offers the possibility of meeting EFA requirements in smaller volumes given the greater EPA and DHA concentrations. This is of potential benefit in PN-dependent neonates with respiratory distress syndrome, in whom minimizing intravenous fluid volume may be important to optimize respiratory function. However, to date, no study has addressed the safety of PFO versus NFO as parenteral fat sources.
Here, we demonstrate that the 20% PFO emulsions were poorly tolerated and resulted in adverse end-organ sequelae while 20% NFO emulsions were well tolerated when administered as monotherapy. Improving the reesterification efficiency of the PFO improved clinical tolerance but still resulted in histologic abnormalities. These data suggest that PFO oils meeting the European Pharmacopoeia monograph 1352 ("omega-3 acids") may result in adverse end-organ effects even if they appear to be well tolerated clinically.
It remains uncertain which part of the process of generating PFO from NFO confers physiologically incompatible properties to PFO for intravenous administration. One possibility is that while the unprocessed fatty acids in NFO are virtually all in triglyceride form, generation of PFO requires hydrolysis of triglycerides to purify and enrich EPA and DHA fatty acids, followed by reesterification. If the reesterification process is not 100% efficient, the resulting oil contains fatty acids in diglyceride, monoglyceride, and free fatty acid form, in addition to triglycerides. This study demonstrates that while increasing the reesterification efficiency from 66% to 90% improved clinical tolerance of the PFO emulsions, both emulsions resulted in adverse endorgan sequelae. To further investigate whether fatty acids in nontriglyceride form contribute to the poor tolerance of PFO emulsions, studies would need to be performed that use either (1) emulsions containing PFO reesterified to triglycerides with near 100% efficiency or (2) complete removal of nontriglyceride fats from PFO. However, such oils are not currently available. It is also possible that an alternative emulsion compounding method could yield a safe, well-tolerated 20% PFO emulsion; however, a new technique for compounding emulsions would have to be developed.
This study provides preclinical evidence suggesting caution in the use of PFO sources meeting the European Pharmacopoeia monograph 1352, "omega-3 acids," as the sole source in 20% parenteral lipid emulsions. PFO with reesterification efficiency up to 90% resulted in adverse effects on livers, spleens, and lungs. It is notable that despite clinically appearing to tolerate the PFO90 emulsion, mice still experienced adverse end-organ effects. These data suggest caution in using even highly reesterified PFO in parenteral emulsions at lower concentrations, especially in patients with long-term PN dependence in whom adverse end-organ effects may be cumulative. Furthermore, 20% NFO emulsions were well tolerated, and they preserved organ integrity similar to the commercially available 10% NFO emulsion. Use of 20% NFO emulsions could provide a means of reducing the volume necessary to administer to meet EFA and fat calorie requirements for PN-dependent patients with intravenous volume restrictions. Additionally, these results indicate that 20% NFO and SO emulsions compounded in the laboratory, which were safe and well tolerated in our mouse model, may be used as research tools to better understand the role of parenteral fat in modulating systemic inflammation and PN-related hepatic toxicity.
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